The newest weight loss drug on the market is facing a shortage of supply, according to the U.S. Food and Drug Administration. The FDA approved Zepbound in November as a weight loss management treatment for people with obesity, or those who are overweight with at least one related underlying condition, such as high blood pressure. As a diabetes drug, Zepbound is sold under the brand name Mounjaro, as the two medications contain the same active ingredient, tirzepatide.